HC Wainwright Reaffirms Buy Rating for Imunon (NASDAQ:IMNN)

Imunon (NASDAQ:IMNN)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They presently have a $12.00 target price on the stock.

Several other equities analysts have also issued reports on IMNN. EF Hutton Acquisition Co. I upgraded Imunon to a “strong-buy” rating in a research note on Monday, September 23rd. D. Boral Capital reaffirmed a “buy” rating and issued a $29.00 price objective on shares of Imunon in a research note on Tuesday.

Imunon Stock Performance

IMNN stock opened at $0.85 on Wednesday. Imunon has a 52 week low of $0.48 and a 52 week high of $3.65. The company’s 50-day simple moving average is $0.89 and its 200 day simple moving average is $1.10. The company has a market capitalization of $12.32 million, a PE ratio of -0.45 and a beta of 2.12.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.